^
    almost2years
    Evaluation of replication protein A inhibitor, NERx329 in combination with EGFR mutant targeted therapy (AACR 2023)
    Osimertinib is a third-generation EGFR-Tyrosine Kinase inhibitor (TKI) that has activity against EGFR exon 19, exon 21, and T790M mutations...AXL and STAT inhibition are associated with induced DNA damage and impaired DNA repair. From these data, we infer that DNA damage repair pathways could be involved in TKI resistance and NERx329 could be a promising drug candidate for combination targeted therapy.
    Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • EGFR T790M • EGFR overexpression • MET mutation • AXL overexpression • AXL-L • AXL underexpression
    |
    Tagrisso (osimertinib)